Dihydromyricetin alleviates attention deficit hyperactivity disorder by modulating the SIRT1/Nrf2/Keap1/HO-1 signaling pathway.

ABSTRACT: Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, with limited effective treatments available. This study investigated the therapeutic potential of Dihydromyricetin (DMY) in a monosodium glutamate (MSG)-induced ADHD mouse model. Behavioral tests, including open field, Y-maze, and social interaction tests, were conducted to assess hyperactivity, attention, and social behavior. Molecular mechanisms were evaluated through Western blot analysis of oxidative stress markers (MDA, GPx, MPO) and key signaling proteins (SIRT1, Keap1, Nrf2, HO-1), as well as ELISA measurement of inflammatory cytokines (NF-κB, IL-6, TNF-α, IL-1β). Histological analysis assessed neuronal damage in the hippocampus and

SUBMITTER: Zang H 

PROVIDER: S-EPMC12802287 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature